irocumab-pcsk9-denial">Praluent Insurance Denied? How to Appeal Your Alirocumab PCSK9 Denial

Praluent (alirocumab) is a PCSK9 inhibitor proven to dramatically lower LDL cholesterol and reduce cardiovascular events in high-risk patients. Like its sibling drug Repatha (evolocumab), Praluent faces extremely high Denial Rates by Insurer (2026)" class="auto-link">denial rates from insurance companies due to its cost. If you've been denied, here's what you need to know to fight back effectively.

What Praluent Treats and Why Patients Need It

Praluent is a fully human monoclonal antibody that inhibits PCSK9, allowing the liver to clear more LDL cholesterol from the blood. FDA-approved indications include:

• Adults with established cardiovascular disease (prior MI, stroke, or peripheral artery disease): reduces risk of MI, stroke, and cardiovascular death
• Adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH): used as an adjunct to diet and maximally tolerated statin therapy
• Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients age 8 and older

The ODYSSEY OUTCOMES trial showed that Praluent reduced major cardiovascular events by 15% in patients after an acute coronary syndrome who were on maximally tolerated statin therapy. For patients who have already survived a heart attack and remain at high risk, this degree of additional protection is clinically meaningful.

Why Insurers Deny Praluent

Step therapy requirements: The most common barrier. Insurers require documented use of maximally tolerated statin therapy — and usually ezetimibe as well — before approving a PCSK9 inhibitor. Some plans require two or more statins to have been tried at maximum tolerated doses.

LDL threshold not met: Plans often require LDL ≥70 mg/dL (or higher) while on statin therapy. If your LDL has dropped to near-normal on statins but remains above goal, the insurer may still deny because they consider the level "adequate."

Indication not covered: If your prescribing indication is primary prevention rather than established ASCVD or FH, some plans will not cover PCSK9 inhibitors at all.

Statin intolerance not documented: Patients who can't tolerate statins face extra scrutiny. Insurers may require formal documentation of statin intolerance trials — multiple statins at various doses with documented adverse effects.

Formulary preference for Repatha: Some plans cover Repatha but not Praluent, or vice versa. If you're prescribed Praluent and the plan prefers Repatha, you may receive a denial with a recommendation to switch.

Step-by-Step: How to Appeal a Praluent Denial

Step 1: Identify the denial reason precisely. Was it step therapy, LDL threshold, statin intolerance documentation, or indication? Each requires a targeted response.

Step 2: Compile your lipid management history. Document every statin tried — name, dose, duration, reason for stopping or not increasing dose, and LDL results at each point. Include ezetimibe if used.

Step 3: Have your prescribing physician or lipidologist write a Letter of Medical Necessity. The LMN should address your cardiovascular risk, current LDL, prior therapy history, and why alirocumab is medically appropriate and necessary.

Step 4: Provide supporting labs. Current LDL panel, fasting lipid profile, and any genetic testing for FH (if applicable) should accompany your appeal.

Step 5: Address step therapy requirements directly. If you've completed the required steps, your appeal should clearly document this. If the required steps are contraindicated (due to statin intolerance, drug interactions, etc.), explain why step therapy is clinically inappropriate.

Step 6: Request a peer-to-peer review. This is particularly effective when a cardiologist or lipidologist conducts the review — their specialty expertise adds credibility.

Step 7: File an external appeal if the internal appeal is denied.

What to Include in Your Praluent Appeal Letter

• Member ID, policy number, denial date, and claim reference
• Praluent (alirocumab) dose and indication
• Your cardiovascular history: prior MI, stroke, PAD, FH diagnosis
• Lipid panel results showing LDL levels on current therapy
• Documented history of statins tried (names, doses, duration, adverse effects)
• Ezetimibe trial documentation if required by plan
• Letter of Medical Necessity from cardiologist or lipidologist
• ODYSSEY OUTCOMES trial citation
• ACC/AHA cholesterol guidelines supporting PCSK9 inhibitors in high-risk patients
• Any FH diagnostic criteria or genetic testing results if applicable

Success Tips for Praluent Appeals

Request the plan's specific PA criteria. Every insurer has coverage criteria for PCSK9 inhibitors. Ask for them in writing. Then address each criterion systematically in your appeal letter. This shows you've done your homework and leaves no room for ambiguity.

Document the clinical stakes. If you've already had a heart attack or stroke, your appeal should emphasize that you are at very high risk for a second event and that guideline-recommended intensification of LDL-lowering therapy is indicated.

Distinguish from Repatha if relevant. If the plan prefers Repatha but you've already been on Praluent with a documented good response, ask your physician to document the clinical reason that switching agents would be inappropriate.

Know FH criteria. Patients with FH — characterized by extremely high LDL from a young age, family history of premature cardiovascular disease, and possibly tendon xanthomas — have strong coverage arguments because FH patients often cannot achieve LDL goals with statins alone.

Appeal promptly. Deadlines for internal appeals vary by plan (30–180 days from denial). Don't wait.

Fight Back With ClaimBack

PCSK9 inhibitor denials are a widespread problem — but they are frequently overturned when patients appeal with proper documentation. ClaimBack guides you through every step of the appeal process so you can get the medication your doctor prescribed.

Start your Praluent appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals